Probiotic treatment with viable <scp>α‐galactosylceramide</scp>‐producing <i>Bacteroides fragilis</i> reduces diabetes incidence in female nonobese diabetic mice
B. fragilis induced iNKT cells and M2 macrophages and reduced type 1 diabetes in NOD mice. The protective effect seemed to be more centered on gut-pancreas interactions rather than a systemic immunosuppression. B. fragilis should be considered for probiotic use in individuals at risk of developing type 1 diabetes.
Authors
- Camilla Hartmann Friis Hansen (ORCID: https://orcid.org/0000-0002-1860-385X)
- Danica Jozipović (ORCID: https://orcid.org/0009-0001-3021-8057)
- Karsten Buschard (ORCID: https://orcid.org/0000-0002-0126-7423)
- Axel Kornerup Hansen (ORCID: https://orcid.org/0000-0003-1575-2507)
- Line Fisker Zachariassen (ORCID: https://orcid.org/0000-0001-5425-9841)
- Dennis Sandris Nielsen (ORCID: https://orcid.org/0000-0001-8121-1114)
Institutions
- University of Copenhagen (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Journal of Diabetes
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1111/1753-0407.13593
- Citations
- 3
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.65